License the latest technology from Imperial College London

Technology available for licensing

Imperial College London is among the world’s leading research universities, and one of the few focused exclusively on Science, Technology, Engineering, Medicine and Business. Technology developed by Imperial’s world-leading researchers is protected and packaged by our expert commercialisation specialists. 

Available technologies span all areas of research undertaken at Imperial. If your business is considering licensing technology, you can view available technologies and enquire directly through this site.

Available technologies

Browse technologies and innovations derived from research undertaken by academics at Imperial College London

HKMT Inhibitors

Small molecule inhibitors with potential for use in the treatment of neurodegenerative diseases such as Huntington's disease, viral conditions such as HIV, and cancers

Smartphone Ballistocardiogram App

Smart phone Ballistocardiography (BCG) is a novel measurement method that requires fewer sensors (≥ 1) placed above the heart. It measures the physical movement of the chest due to the heart beating rather than electrical signals measured by ECG

Licensing and IP performance 2019/20

Inventions disclosed

Imperial inventors submitted 250 invention disclosures to our IPC team during the year

Active licences

Imperial College London's licensing portfolio comprises 244 licences

Patents filed

Imperial filed 137 patents (including PCT applications) during the year

Patent portfolio

Imperial's patent portfolio reached 331 patents during the year

Featured inventor

Upcoming Events

Imperial.tech.pitch events – learn more and sign up

Imperial.tech.pitch events – learn more and sign up

Event date - October 1, 2023

Learn about our programme of events and sign up to be alerted for future events Find out more

Latest News

Accelerated development of a potential treatment for cystic fibrosis

Accelerated development of a potential treatment for cystic fibrosis

The UK Cystic Fibrosis Gene Therapy Consortium (GTC) is one of the partners in a licensing agreement with Boehringer Ingelheim. Find out more

Natural Killer – licensing a cell therapy

Natural Killer – licensing a cell therapy

Imperial has licensed iNKT cell technology based on research by Prof. Tassos Karadimitris to SUDA Pharmaceuticals. Find out more

Imperial partner Apollo receives £100m to boost medical research at leading unis

Imperial partner Apollo receives £100m to boost medical research at leading unis

Imperial will benefit from continued support for translational biomedical research under a unique technology transfer model. Find out more

Sign up for updates

Sign up for monthly technology alerts via email, and find other ways to connect with us.

Loading...